Navigation Links
Crestor and Zocor Drugs Linked to Muscle Degeneration, Rhabdomyolysis
Date:7/15/2011

EDISON, N.J., July 15, 2011 /PRNewswire/ -- Crestor and Zocor are widely-used prescription strength drugs designed to lower "bad cholesterol". Both drugs are classified as "statins", medicine which lowers blood cholesterol levels by inhibiting HMG-CoA reductase. This group of drugs has had a controversial history, starting with Baycol, a drug similar to Crestor and Zocor, touted as a "super statin" before its recall from the market. Despite numerous objections from medical researchers and reputable consumer groups due to safety concerns, the drug was approved by the FDA in August of 2003, and launched a month later. Even before their FDA approval, these drugs showed signs of being linked to serious muscle and kidney problems, including the potentially fatal, muscle-destroying condition rhabdomyolysis.

Zocor and Crestor are strongly marketed by their parent companies, Merck and AstraZeneca respectively. By early 2004, 27% of all new prescriptions for statin drugs were for Crestor. The Wall Street Journal reported:

"AstraZeneca sales force (Crestor) was making more calls to doctors than any of its competitors. Beginning in late February, reflecting the sales calls, new prescriptions of Crestor began to rise and overtook Lipitor by the beginning of March 20."

This style of pharmaceutical marketing is so effective that in 2010, the statin Lipitor was the #1 selling drug in America by unit, with Crestor at #6.

Warning-sign side effects include:

  • muscle pain, tenderness, or weakness
  • lack of energy
  • fever
  • chest pain
  • yellowing of the skin or eyes
  • pain in the upper right part of the abdomen
  • nausea
  • extreme tiredness
  • unusual bleeding or bruising
  • loss of appetite
  • flu-like symptoms
  • sore throat, chills, or other signs of infection
  • rash
  • hives
  • itching
  • difficulty breathing or swallowing
  • swelling of the face, throat tongue, lips, eyes, hands, feet, ankles, or lower legs
  • hoarseness
  • numbness or tingling in the fingers or toes

These drugs are extremely profitable for the companies that market, produce, and sell them, as well as potentially, extremely dangerous for those who pay for and consume them. Lawsuits are currently being brought against the companies producing Zocor and Crestor. Many people across America have experienced unnecessary and dangerous side-effects as a result of these drugs. One of the law offices conducting lawsuits into both Crestor and Zocor is Eichen Crutchlow Zaslow & McElroy, LLP located in Edison, New Jersey and Toms River, New Jersey, a legal group with a history of award-winning legal services in the tri-state area and nationally in matters involving catastrophic personal injury, mass torts, medical malpractice, class actions, and consumer fraud litigation. Those who have been injured by Crestor or Zocor use should not hesitate to contact a lawyer.

Contact: Angela McKillop
Amckillop@njadvocates.com
NJAdvocates.com
Tel: (732) 777-0100
Fax: (732) 248-8273


'/>"/>
SOURCE Eichen Crutchlow Zaslow & McElroy, LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
4. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
5. CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study
6. CRESTOR(R) Reduced Risk of Blood Clots in the Veins
7. CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis
8. CRESTOR(R) Reduced Risk of Cardiovascular Events in Elderly Patients in New Analysis of Jupiter
9. U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
10. Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study
11. Advisory Committee Briefing Materials for CRESTOR(R) sNDA Available on US FDA Web Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at www.diabetesscholars.org by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
(Date:6/24/2016)... MD (PRWEB) , ... June 24, 2016 , ... ... protocols for human induced pluripotent stem (iPS) cells and other difficult to transfect ... G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is a ...
Breaking Medicine News(10 mins):